Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2021 Jan 19;19(1):11.
doi: 10.1186/s13053-021-00168-z.

A novel frequent BRCA1 recurrent variant c.5117G > A (p.Gly1206Glu) identified after 20 years of BRCA1/2 research in the Baltic region: cohort study and literature review

P Loza  1   2 , A Irmejs  3 , Z Daneberga  3 , E Miklasevics  3 , E Berga-Svitina  3 , S Subatniece  3 , J Maksimenko  3 , G Trofimovics  4 , E Tauvena  4 , S Ukleikins  4 , J Gardovskis  4
Affiliations

A novel frequent BRCA1 recurrent variant c.5117G > A (p.Gly1206Glu) identified after 20 years of BRCA1/2 research in the Baltic region: cohort study and literature review

P Loza et al. Hered Cancer Clin Pract. .

Abstract

Background: Several recent studies in the Baltic region have found extended spectrum of pathogenic variants (PV) of the BRCA1/2 genes. The aim of current study is to analyze the spectrum of the BRCA1/2 PV in population of Latvia and to compare common PV between populations of the Baltic region.

Methods: We present a cohort of 9543 unrelated individuals including ones with cancer and unaffected individuals from population of Latvia, who were tested for three most common BRCA1 founder PV. In second line testing, 164 founder negative high-risk individuals were tested for PV of the BRCA1/2 using next generation sequencing (NGS). Local spectrum of the BRCA1/2 PV was compared with the Baltic region by performing a literature review.

Results: Founder PV c.5266dupC, c.4035delA or c.181 T > G was detected in 369/9543 (3.9%) cases. Other BRCA1/2 PV were found in 44/164 (26.8%) of NGS cases. Four recurrent BRCA1 variants c.5117G > A (p.Gly1706Glu), c.4675G > A (p.Glu1559Lys), c.5503C > T (p.Arg1835*) and c.1961delA (p.Lys654fs) were detected in 18/44 (41.0%), 5/44 (11.4%), 2/44 (4.5%) and 2/44 (4.5%) cases respectively. Additionally, 11 BRCA1 PV and six BRCA2 PV were each found in single family.

Conclusions: By combining three studies by our group of the same cohort in Latvia, frequency of the BRCA1/2 PV for unselected breast and ovarian cancer cases is 241/5060 (4.8%) and 162/1067 (15.2%) respectively. The frequency of three "historical" founder PV is up to 87.0% (369/424). Other non-founder PV contribute to at least 13.0% (55/424) and this proportion probably will rise by increasing numbers of the BRCA1/2 sequencing. In relative numbers, c.5117G > A is currently the third most frequent PV of the BRCA1 in population of Latvia, overcoming previously known third most common founder variant c.181 T > G. In addition to three BRCA1 founder PV, a total of five recurrent BRCA1 and two recurrent BRCA2 PV have been reported in population of Latvia so far. Many of the BRCA1/2 PV reported in Latvia are shared among other populations of the Baltic region.

Keywords: BRCA1; BRCA2; C.181 T > G; C.1961delA (p.Lys654fs); C.4035delA; C.4675G > A (p.Glu1559Lys); C.5117G > A (p.Gly1706Glu); C.5266dupC; C.5503C > T (p.Arg1835*).

PubMed Disclaimer

Conflict of interest statement

All authors declare that they have no competing interests.

Similar articles

See all similar articles

Cited by

References

    1. Gorski B, Byrski T, Huzarski T, Jakubowska A, Menkiszak J, Gronwald J, Płuzanska A, Bebenek M, Fischer-Maliszewska Ł, Grzybowska E, Narod SA. J. Lubin ski "founder mutations in the BRCA1 gene in polish families with breast-ovarian Cancer". Am J Hum Genet. 2000;66:1963–1968. doi: 10.1086/302922. - DOI - PMC - PubMed
    1. Tikhomirova L, Sinicka O, Smite D, Eglitis J, Hodgson SV. Aivars Stengrevics "high prevalence of two BRCA1 mutations, 4154delA and 5382insC, in Latvia". Familial Cancer. 2005;4:77–84. doi: 10.1007/s10689-004-2758-3. - DOI - PubMed
    1. Csokay B, Tihomirova L, Stengrevics A, Sinicka O, Olah E "Strong founder effects in BRCA1 mutation carrier breast cancer patients from Latvia," Mutation in brief no. 258, vol. 14, no. 92, 1999. DOI: 10.1002/(sici)1098-1004(1999)14:1<92::aid-humu23>3.0.co;2–2. - PubMed
    1. Gardovskis A, Irmejs A, Miklasevics E, Borosenko V, Bitina M, Melbarde-Gorkusa I, Vanags A, Kurzawski G, Suchy J, Górski B, Gardovskis J. Clinical, molecular and geographical features of hereditary breast/ovarian Cancer in Latvia. Hered Cancer Clin Pract. 2005;3(2):71–76. doi: 10.1186/1897-4287-3-2-71. - DOI - PMC - PubMed
    1. Tihomirova L, Vaivade I, Fokina O, Peculis R, Mandrika I, Sinicka O, Stengrevics A, Krilova A, Keire G, Petrevics J, Eglitis J, Timofejevs M, Leja M. BRCA1 gene-related hereditary susceptibility to breast and ovarian cancer in Latvia. Adv Med Sci. 2014;59. 10.1016/j.advms.2013.09.002. - PubMed

LinkOut - more resources